Assay

ELISpot and FluoroSpot Assay Market Report 2022: Use of FluoroSpot Assays for Multiple-Analyte Detection in Single Well Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Friday, November 25, 2022
Research, Other Health, General Health, Medical Devices, Infectious Diseases, Hospitals, Health Technology, Science, COVID-19, Biotechnology, Medical Supplies, Health, Other Science, ELISpot, Growth, Hospital, ELISA, Research, Transplant, Biotechnology, USD, Diagnosis, NCD, Vaccine, Assay, Analyser

Market is driven by factors such as Increasing use of ELISpot and FluoroSpot assays in oncology, growth in biotechnology and biopharmaceutical industries.

Key Points: 
  • Market is driven by factors such as Increasing use of ELISpot and FluoroSpot assays in oncology, growth in biotechnology and biopharmaceutical industries.
  • The Assay kits accounted for the largest market share in the ELISpot and FluoroSpot Assays product' market, during the forecast period
    The ELISpot and FluoroSpot Assay Products market is segmented into Assay kits, Analyzers, and Ancillary Products.
  • Based on type of application, the ELISpot and FluoroSpot Assays market is segmented into Diagnostic and Research Application.
  • The global ELISpot and FluoroSpot Assays market is divided into four regions: North America, Asia-Pacific, Europe, and Rest of the World.

INDIGO Biosciences Receives Approval from California Water Boards for Use of Its Bioassays in Recycled Water Monitoring

Retrieved on: 
Tuesday, November 15, 2022
Health, Aryl hydrocarbon receptor, Environment, Estradiol, California State Water Resources Control Board, ER, Water, CECS, Hydrocarbon, Estrogen, INDIGO, Cancer, Pesticide, CEO, Drug discovery, Science, Estrogen receptor alpha, Environmental remediation, Assay

STATE COLLEGE, Pa., Nov. 15, 2022  /PRNewswire-PRWeb/ -- INDIGO Biosciences, Inc. has received approval from the California Water Boards, State Water Resources Control Board, for the use of two of its bioassays in recycled water monitoring. INDIGO has been approved for the use of its Aryl Hydrocarbon Receptor (AhR) and Estrogen Receptor Alpha (ERα) bioassays as bioanalytical screening tools for Constituents of Emerging Concern (CECs) in recycled water.

Key Points: 
  • STATE COLLEGE, Pa., Nov. 15, 2022 /PRNewswire-PRWeb/ -- INDIGO Biosciences, Inc. has received approval from the California Water Boards, State Water Resources Control Board , for the use of two of its bioassays in recycled water monitoring.
  • INDIGO has been approved for the use of its Aryl Hydrocarbon Receptor (AhR) and Estrogen Receptor Alpha (ER) bioassays as bioanalytical screening tools for Constituents of Emerging Concern (CECs) in recycled water.
  • We look forward to developing additional bioassays that can help water boards and regulators everywhere monitor for contaminants that pose potential environmental and health risks."
  • As part of the approval process, INDIGO submitted validation packages for both its AhR and ER assays.

Enterome's OncoMimics™ peptide-based immunotherapy EO2401 generates and maintains elevated anti-tumor T cell responses for more than 10 months in patients with recurrent glioblastoma

Retrieved on: 
Thursday, November 10, 2022
UCP2, Assay, IL13RA2, PFS, Protein, Nivolumab, Bevacizumab, CD4, TAAS, FOXM1, Annual general meeting, Peptide, Immunotherapy, Neoplasm, LDB, Population, Data, Glioblastoma, Safety, Cancer, Vaccination, Observation, Maintenance, Poster, Society for Immunotherapy of Cancer, Molecular mimicry, Patient, Memory, Therapy, BIRC5, ORR, SITC, Vaccine, Pharmaceutical industry

PARIS, Nov. 10, 2022 /PRNewswire/ -- Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial Mimicry drug discovery platform, today announces updated safety, immunogenicity and efficacy data of its Phase 1/2 clinical trial of EO2401 in combination with an immune checkpoint inhibitor (nivolumab) +/- an anti-VEGF therapy (bevacizumab), for the treatment of patients with first progression/recurrence of glioblastoma (ROSALIE trial). The data were presented in an oral and a poster presentation at the 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Boston, MA, US, today.

Key Points: 
  • EO2401 includes synthetically produced HLA-A2 peptides with molecular mimicry to TAAs upregulated in glioblastoma (IL13Ra2, BIRC5 and FOXM1) and the CD4 helper peptide UCP2.
  • EO2401 in combination with nivolumab generated strong systemic immune responses through activation of specific effector memory CD8+ T cells, correlating with clinical efficacy.
  • Additional patients are to be treated with triple combination of EO2401 in combination with nivolumab and bevacizumab to support final regimen selection.
  • The trial is assessing safety, tolerability, immunogenicity and preliminary efficacy in approximately 80 patients at centers in the US and Europe.

Enterome's OncoMimics™ peptide-based immunotherapy EO2401 generates and maintains elevated anti-tumor T cell responses for more than 10 months in patients with recurrent glioblastoma

Retrieved on: 
Thursday, November 10, 2022
UCP2, Assay, IL13RA2, PFS, Protein, Nivolumab, Bevacizumab, CD4, TAAS, FOXM1, Annual general meeting, Peptide, Immunotherapy, Neoplasm, LDB, Population, Data, Glioblastoma, Safety, Cancer, Vaccination, Observation, Maintenance, Poster, Society for Immunotherapy of Cancer, Molecular mimicry, Patient, Memory, Therapy, BIRC5, ORR, SITC, Vaccine, Pharmaceutical industry

PARIS, Nov. 10, 2022 /PRNewswire/ -- Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial Mimicry drug discovery platform, today announces updated safety, immunogenicity and efficacy data of its Phase 1/2 clinical trial of EO2401 in combination with an immune checkpoint inhibitor (nivolumab) +/- an anti-VEGF therapy (bevacizumab), for the treatment of patients with first progression/recurrence of glioblastoma (ROSALIE trial). The data were presented in an oral and a poster presentation at the 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Boston, MA, US, today.

Key Points: 
  • EO2401 includes synthetically produced HLA-A2 peptides with molecular mimicry to TAAs upregulated in glioblastoma (IL13Ra2, BIRC5 and FOXM1) and the CD4 helper peptide UCP2.
  • EO2401 in combination with nivolumab generated strong systemic immune responses through activation of specific effector memory CD8+ T cells, correlating with clinical efficacy.
  • Additional patients are to be treated with triple combination of EO2401 in combination with nivolumab and bevacizumab to support final regimen selection.
  • The trial is assessing safety, tolerability, immunogenicity and preliminary efficacy in approximately 80 patients at centers in the US and Europe.

Gb Sciences Co-Publishes Study Demonstrating Anti-Inflammatory Properties of Cannabis Ingredients

Retrieved on: 
Tuesday, November 1, 2022
Olive, Security (finance), THC, Depression, Nature, National Research Council, Food and Chemical Toxicology, Cannabinol, Assay, Inflammation, U.S. Securities and Exchange Commission, GBLX, CBC, Chaminade University of Honolulu, CBDV, Good manufacturing practice, Biomarker, Clinical trial, GLOBE, Parkinson's disease, Hospital, COVID-19, Immune system, Michigan State University, CBN, Cannabinoid, Terpene, Anxiety, University, Cannabidiol, Company, CBG, Prevalence, Cytokine release syndrome, Contract, Sativum, OTCQB, Chronic pain, Nonsteroidal anti-inflammatory drug, Pharmaceutical industry, CBD, Cannabis

Andrea Small-Howard, President, Chief Science Officer, and Director of Gb Sciences.

Key Points: 
  • Andrea Small-Howard, President, Chief Science Officer, and Director of Gb Sciences.
  • Gb Sciences selected the specific Cannabis constituents for this study based on their prior activity within chemovar studies.
  • Gb Sciences' intellectual property portfolio contains six issued U.S. and three issued foreign patents, as well as 17 U.S. and 51 foreign patent-pending applications.
  • Gb Sciences' formulations for chronic pain, anxiety, and depression are currently in preclinical animal studies with researchers at the National Research Council of Canada.

OROCO CONTINUES EXPANSION OF NORTH ZONE AND EXTENDS STRIKE LENGTH AT BRASILES

Retrieved on: 
Tuesday, October 25, 2022
OTC, Assay, Geology, GLOBE, Plate, Cross, Company, 3D, Economy, Hypleurochilus brasil, CEO, OCO, Program, News, NE, NNE, Monzonite, Road, Uranium, Printed circuit board, Mining

Drill hole N028 extended the confirmed strike length of the North Zone approximately 100 m further north of N013, the previous most northerly drill hole in the North Zone.

Key Points: 
  • Drill hole N028 extended the confirmed strike length of the North Zone approximately 100 m further north of N013, the previous most northerly drill hole in the North Zone.
  • Assay results and cross-sections through the first thirty-one North Zone drill holes (21,379 m of drilling) and the first seven Brasiles Zone drill holes (5,116.36 m) are available at the Companys website.
  • Drill holes B006 and B007 (see Figure 2) continued the Companys testing of the western fringe of the Brasiles West Zone, which has strong geological similarities to the North Zone.
  • The Brasiles West Zone lies beneath a blanket of limestone in a westerly dipping, NE-trending zone of faulting and monzonite intrusion.

Global Cell-based Assay Market Report 2022: Demand from Biotechnology and Pharmaceutical Sector for Drug Development Applications Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 27, 2022
Biotechnology, Pharmaceutical, Health, Biotechnology, Protein, Growth, Assay, Tissue, Cell, Revenue, RNA transfection, CAGR, Vaccine, Drug development, Cell proliferation, USD, Drug discovery, Fine chemical

The global cell-based Assay market size is expected to reach USD 32.23 billion by 2030.

Key Points: 
  • The global cell-based Assay market size is expected to reach USD 32.23 billion by 2030.
  • The growing demand for cell-based assays in the biotechnology and pharmaceutical sector for drug development applications is expected to drive market growth.
  • Furthermore, increasing penetration of the many non-curable diseases where vaccine development and drug discovery is one of the major factors driving demand.
  • The publisher has segmented the Cell-based assay market report based on Product, type, end-use, and region:
    Cell-based Assay, Product Outlook (Revenue - USD Billion, 2018 - 2030)

Enable Biosciences' Co-founder Carolyn Bertozzi Awarded Nobel Prize in Chemistry

Retrieved on: 
Monday, October 10, 2022
SAN, CAP, CLIA, Disease, Assay, Laboratory, Food allergy, COVID, Nobel Prize, Stanford University, Royal Swedish Academy of Sciences, MBA, Technology, HIV, Student, University of California, Berkeley, Doctor of Philosophy, Nobel Prize in Chemistry, Science, CEO, UC, Diabetes, College, M.D, Click chemistry, COVID-19, Biomarker, Pharmaceutical industry, Management, Chemistry, Enabling (disambiguation)

SOUTH SAN FRANCISCO, Calif., Oct. 10, 2022 /PRNewswire/ -- Enable Biosciences, a leading diabetes and COVID diagnostics firm and CLIA- and CAP- certified laboratory, announced that Carolyn Bertozzi, PhD, co-founder of Enable Biosciences, was awarded the 2022 Nobel Prize in Chemistry for "the development of click chemistry and bioorthogonal chemistry."

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Oct. 10, 2022 /PRNewswire/ -- Enable Biosciences, a leading diabetes and COVID diagnostics firm and CLIA- and CAP- certified laboratory, announced that Carolyn Bertozzi, PhD, co-founder of Enable Biosciences, was awarded the 2022 Nobel Prize in Chemistry for "the development of click chemistry and bioorthogonal chemistry."
  • Dr. Bertozzi in particular was cited for her development of bioorthogonal chemistry, a set of bond-forming reactions that are able to proceed in biological settings without interference from or interfering with living systems.
  • We are immensely proud of her passion, persistence and peerless performance," said David Seftel, M.D, MBA, CEO, Chief Medical Officer and co-founder at Enable.
  • Enable operates a CLIA- and College of American Pathologists (CAP) - certified high complexity reference laboratory in South San Francisco.

Global Bioanalytical Testing Services Markets, 2021-2022 & 2027: Leading Growth Opportunity Areas in Customized Bioassay and Biomarker Testing Services - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 5, 2022
Pharmaceutical, Health, Biometrics, Adoption, LIMS, Cros, RNA transfection, Assay, PD, Growth, Drug development, Artificial intelligence, Technology, Drug discovery, Industry, Pharmacokinetics, Ecosystem, CRO, COVID-19, Solution, Toxicology, Semiconductor, Fine chemical

This report on global bioanalytical testing services identifies some of the leading growth opportunity areas in terms of customized bioassay and biomarker testing services, highlighting the growing trend of CRO subcontracting to specifically cater to the specialized drug development and accuracy needs.

Key Points: 
  • This report on global bioanalytical testing services identifies some of the leading growth opportunity areas in terms of customized bioassay and biomarker testing services, highlighting the growing trend of CRO subcontracting to specifically cater to the specialized drug development and accuracy needs.
  • Bioanalytical testing is one of the core aspects of drug development.
  • The testing modules include biomarker testing, immunogenicity testing, toxicology, pharmacokinetics (PK), and pharmacodynamics (PD).
  • What are key trends driving and restricting the outsourcing of bioanalytical testing services?

Predicine’s Liquid Biopsy Next-Generation Sequencing (NGS) Assay is Granted Breakthrough Device Designation by U.S. Food and Drug Administration

Retrieved on: 
Tuesday, September 20, 2022
CNV Public, Precision medicine, Cdx, Twitter, Infection, SNV calling from NGS data, FDA, Food, Liquid biopsy, LinkedIn, Gene, Urine, Review, DNA sequencing, Nucleic acid thermodynamics, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Cancer, Diagnosis, Assay, De novo, NGS, RNA, Research, DNA, Silicon, GLOBE, HIV disease progression rates, Pharmaceutical industry, Medical imaging

The PredicineCARE cfDNA Assay is being developed to identify biomarker-eligible cancer patients with select indications who may benefit from treatment with targeted therapy.

Key Points: 
  • The PredicineCARE cfDNA Assay is being developed to identify biomarker-eligible cancer patients with select indications who may benefit from treatment with targeted therapy.
  • We are excited about FDAs decision to grant Breakthrough Device designation to the PredicineCARE cfDNA Assay, said Shidong Jia, Predicines Founder and Global CEO.
  • This is a significant milestone achievement in our journey to advancing liquid biopsy precision medicine and accelerating accessibility for cancer patients.
  • We look forward to further developing the PredicineCARE cfDNA Assay as a potential companion diagnostic test under the Breakthrough Devices Program.